Concomitant Essential Thrombocythemia With Jak2 V617f Mutation In A Patient With Chronic Myeloid Leukemia With Major Molecular Response With Imatinib And Long-term Follow-up

dc.creatorBarbosa Pagnano
dc.creatorKatia Borgia; Delamain
dc.creatorMarcia Torresan; Magnus
dc.creatorMariana Munari; Vassallo
dc.creatorJose; De Souza
dc.creatorCarmino Antonio; De Almeida
dc.creatorDaiane; Lorand-Metze
dc.creatorIrene
dc.date2016
dc.datejul
dc.date2017-11-13T13:24:43Z
dc.date2017-11-13T13:24:43Z
dc.date.accessioned2018-03-29T05:57:14Z
dc.date.available2018-03-29T05:57:14Z
dc.identifierOncology Letters. Spandidos Publ Ltd, v. 12, p. 485 - 487, 2016.
dc.identifier1792-1074
dc.identifier1792-1082
dc.identifierWOS:000379960200080
dc.identifier10.3892/ol.2016.4631
dc.identifierhttps://www.spandidos-publications.com/ol/12/1/485
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/328363
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1365388
dc.descriptionThe association of chronic myeloid leukemia (CML) with other myeloproliferative neoplasms (MPNs), in particular with the V617F mutation in the Janus kinase 2 (JAK2) gene, is very uncommon, and there are only a few cases reported in the literature. In the present study, the case of a 73-year-old man with CML and persistent thrombocytosis, is reported. The patient achieved a complete cytogenetic response and major molecular response (MR) with imatinib. The patient presented JAK2 V617F mutation, and bone marrow morphology was consistent with essential thrombocythemia. The patient was treated with imatinib and hydroxyurea to control the platelet count, and maintains complete MR with imatinib upon 10 years of follow-up. Although rare, the association of breakpoint cluster region-Abelson rearrangement and JAK2 V617F mutation should be investigated in patients with MPN, since both genetic anomalies may be present at diagnosis or may emerge during treatment, and require different therapeutic approaches.
dc.description12
dc.description1
dc.description485
dc.description487
dc.languageEnglish
dc.publisherSpandidos Publ Ltd
dc.publisherAthens
dc.relationOncology Letters
dc.rightsfechado
dc.sourceWOS
dc.subjectChronic Myeloid Leukemia
dc.subjectMyeloproliferative Neoplasms
dc.subjectEssential Thrombocythemia
dc.subjectJak2 V617f Mutation
dc.subjectBcr-abl
dc.subjectImatinib
dc.subjectMolecular Response
dc.titleConcomitant Essential Thrombocythemia With Jak2 V617f Mutation In A Patient With Chronic Myeloid Leukemia With Major Molecular Response With Imatinib And Long-term Follow-up
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución